pI: 9.8612 |
Length (AA): 734 |
MW (Da): 83377 |
Paralog Number:
2
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 4 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
12 | 148 | 3pe6 (A) | 7 | 148 | 24.00 | 0.0027 | 0.98 | 0.449248 | -0.54 |
237 | 316 | 3add (A) | 174 | 248 | 37.00 | 0.36 | 0.16 | 0.462292 | -0.63 |
348 | 627 | 4u0r (A) | 161 | 488 | 18.00 | 0.065 | 0.14 | 0.525071 | -0.59 |
411 | 528 | 3ult (A) | 5 | 115 | 32.00 | 0.013 | 0.03 | 0.439063 | -0.81 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | intra-erythrocytic - 0 hs, intra-erythrocytic - 8 hs, intra-erythrocytic - 40 hs, intra-erythrocytic - 48 hs, Sporozoite, Female Gametocyte. | Otto TD Zanghi G Lasonder E |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | intra-erythrocytic - 16 hs, Ring. | Otto TD Zanghi G |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | intra-erythrocytic - 24 hs, intra-erythrocytic - 32 hs. | Otto TD |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | Oocyst, Male Gametocyte. | Zanghi G Lasonder E |
Otto TD | New insights into the blood-stage transcriptome of Plasmodium falciparum using RNA-Seq. |
Zanghi G | A Specific PfEMP1 Is Expressed in P. falciparum Sporozoites and Plays a Role in Hepatocyte Infection. |
Lasonder E | Integrated transcriptomic and proteomic analyses of P. falciparum gametocytes. Molecular insight into sex-specific processes and translational repression. |
Ortholog group members (OG5_127017)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT2G24320 | alpha/beta-Hydrolases superfamily protein |
Arabidopsis thaliana | AT4G31020 | alpha/beta-Hydrolases superfamily protein |
Arabidopsis thaliana | AT3G01690 | alpha/beta-hydrolase domain-containing protein |
Arabidopsis thaliana | AT5G38220 | alpha/beta-Hydrolases superfamily protein |
Arabidopsis thaliana | AT1G66900 | alpha/beta-Hydrolases superfamily protein |
Arabidopsis thaliana | AT1G32190 | alpha/beta-hydrolase-like protein |
Arabidopsis thaliana | AT3G30380 | alpha/beta-Hydrolases superfamily protein |
Arabidopsis thaliana | AT5G14390 | alpha/beta-hydrolasefamily protein |
Arabidopsis thaliana | AT4G24760 | alpha/beta-Hydrolases superfamily protein |
Babesia bovis | BBOV_III007870 | conserved hypothetical protein |
Babesia bovis | BBOV_III007880 | hypothetical protein |
Babesia bovis | BBOV_IV005690 | hypothetical protein |
Brugia malayi | Bm1_20405 | MGC83647 protein |
Caenorhabditis elegans | CELE_K04G2.2 | Protein AHO-3 |
Cryptosporidium hominis | Chro.60574 | similar to CGI-67 protein |
Cryptosporidium hominis | Chro.40175 | hypothetical protein |
Cryptosporidium parvum | cgd6_4990 | predicted peptidase of the alpha/beta-hydrolase fold |
Cryptosporidium parvum | cgd4_1530 | conserved protein |
Drosophila melanogaster | Dmel_CG33096 | CG33096 gene product from transcript CG33096-RG |
Echinococcus granulosus | EgrG_000958300 | Phospholipase carboxylesterase |
Entamoeba histolytica | EHI_004620 | hypothetical protein, conserved |
Entamoeba histolytica | EHI_115820 | hypothetical protein |
Echinococcus multilocularis | EmuJ_000958300 | Phospholipase carboxylesterase |
Giardia lamblia | GL50803_13896 | Cgi67 serine protease precursor-like protein |
Homo sapiens | ENSG00000107362 | abhydrolase domain containing 17B |
Homo sapiens | ENSG00000136379 | abhydrolase domain containing 17C |
Homo sapiens | 101930551 | abhydrolase domain-containing protein FAM108A2/A3-like |
Homo sapiens | ENSG00000129968 | abhydrolase domain containing 17A |
Leishmania braziliensis | LbrM.20.6000 | serine peptidase |
Leishmania braziliensis | LbrM.33.0390 | serine peptidase, putative,serine peptidase, Clan SC, Family S9D |
Leishmania donovani | LdBPK_330410.1 | serine peptidase, putative |
Leishmania donovani | LdBPK_120920.1 | Alpha/beta hydrolase domain-containing protein |
Leishmania infantum | LinJ.12.0920 | serine peptidase, putative,serine peptidase, Clan SC, Family S9D |
Leishmania infantum | LinJ.33.0410 | serine peptidase, putative,serine peptidase, Clan SC, Family S9D |
Leishmania major | LmjF.33.0400 | serine peptidase, putative,serine peptidase, Clan SC, Family S9D |
Leishmania major | LmjF.12.1330 | serine peptidase, putative,serine peptidase, Clan SC, Family S9D |
Leishmania mexicana | LmxM.32.0400 | serine peptidase, putative,serine peptidase, Clan SC, Family S9D |
Leishmania mexicana | LmxM.12.1330 | serine peptidase, putative,serine peptidase, Clan SC, Family S9D |
Loa Loa (eye worm) | LOAG_03978 | hypothetical protein |
Loa Loa (eye worm) | LOAG_06114 | hypothetical protein |
Mus musculus | ENSMUSG00000038459 | abhydrolase domain containing 17C |
Mus musculus | ENSMUSG00000003346 | abhydrolase domain containing 17A |
Mus musculus | ENSMUSG00000047368 | abhydrolase domain containing 17B |
Neospora caninum | NCLIV_025340 | hypothetical protein |
Oryza sativa | 4331009 | Os02g0796600 |
Oryza sativa | 4327946 | Os01g0689800 |
Oryza sativa | 4351997 | Os12g0286600 |
Oryza sativa | 4344723 | Os08g0161500 |
Oryza sativa | 4341592 | Os06g0633900 |
Oryza sativa | 4328574 | Os02g0190800 |
Plasmodium berghei | PBANKA_1225600 | alpha/beta hydrolase, putative |
Plasmodium berghei | PBANKA_1001500 | alpha/beta hydrolase, putative |
Plasmodium falciparum | PF3D7_0805000 | alpha/beta hydrolase, putative |
Plasmodium falciparum | PF3D7_1120400 | alpha/beta hydrolase fold domain containing protein, putative |
Plasmodium falciparum | PF3D7_0403800 | alpha/beta hydrolase, putative |
Plasmodium knowlesi | PKNH_0918100 | alpha/beta hydrolase fold domain containing protein, putative |
Plasmodium knowlesi | PKNH_0114200 | alpha/beta hydrolase, putative |
Plasmodium knowlesi | PKNH_0301800 | alpha/beta hydrolase, putative |
Plasmodium vivax | PVX_093510 | hypothetical protein, conserved |
Plasmodium vivax | PVX_001055 | alpha/beta hydrolase, putative |
Plasmodium vivax | PVX_091652 | hypothetical protein, conserved |
Plasmodium yoelii | PY02448 | hypothetical protein |
Schistosoma japonicum | Sjp_0116590 | Abhydrolase domain-containing protein FAM108C1, putative |
Schistosoma japonicum | Sjp_0026950 | Abhydrolase domain-containing protein FAM108A precursor, putative |
Schistosoma japonicum | Sjp_0049380 | Abhydrolase domain-containing protein FAM108A precursor, putative |
Schistosoma japonicum | Sjp_0026970 | Abhydrolase domain-containing protein FAM108C1, putative |
Schistosoma mansoni | Smp_027000 | family S9 unassigned peptidase (S09 family) |
Schistosoma mansoni | Smp_038830 | peptidase |
Schmidtea mediterranea | mk4.017318.00 | |
Schmidtea mediterranea | mk4.004184.01 | Family S9 unassigned peptidase |
Trypanosoma brucei gambiense | Tbg972.1.3290 | serine peptidase, putative,serine peptidase, Clan SC, Family S9D |
Trypanosoma brucei | Tb927.1.4780 | Alpha/beta hydrolase domain-containing protein |
Trypanosoma congolense | TcIL3000_1_1980 | Alpha/beta hydrolase domain-containing protein |
Trypanosoma cruzi | TcCLB.507711.330 | serine peptidase, putative |
Trypanosoma cruzi | TcCLB.507997.54 | serine peptidase, Clan SC, Family S9D |
Trypanosoma cruzi | TcCLB.509643.90 | serine peptidase, putative |
Trypanosoma cruzi | TcCLB.508593.44 | Alpha/beta hydrolase domain-containing protein |
Toxoplasma gondii | TGME49_262490 | alpha/beta hydrolase, putative |
Theileria parva | TP03_0361 | hypothetical protein, conserved |
Theileria parva | TP04_0691 | hypothetical protein, conserved |
Theileria parva | TP04_0692 | hypothetical protein |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.1.4780 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.1.4780 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.1.4780 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.1.4780 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
PBANKA_1001500 | Plasmodium berghei | Slow | plasmo |
PBANKA_1225600 | Plasmodium berghei | Dispensable | plasmo |
TGME49_262490 | Toxoplasma gondii | Essentiality uncertain | sidik |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.